Canada
Every company in the roster headquartered in Canada.
Every company in the roster headquartered in Canada.
13 of 13 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Xenon PharmaceuticalsXENE · Nasdaq | 1 asset: 1 Ph 3 | AzetukalnerPhase 3 · Major Depressive DisorderReliable signal | Jan 2027Azetukalner · Phase 3 | $3.6B | $951MSep 2026 | ~10.7 qtrs | $371M |
Bausch HealthBHC · NYSE | 15 assets: 13 approved, 1 Ph 3, 1 Ph 2 | Rifaximin SSDPhase 3 | 20 Apr 2027Rifaximin (Xifaxan) · Approved | $3.3B | $2.5BSep 2026 | Cash-flow positive | $638M |
Helus PharmaHELP · Nasdaq | 1 asset: 1 Ph 3 | DeupsilocinPhase 3 · Major Depressive DisorderPartial signal | None on record | $427M | — | — | $39M |
Lexaria BioscienceLEXX · Nasdaq | 2 assets: 1 Ph 1, 1 other | DehydraTECH-CBD/semaglutidePhase 1 · ObesityWeak signal | None on record | $106M | $3.6MMay 2026 | Ended Oct 2026 | $5.3M |
ProMIS Neurosciences, Inc.PMN · Nasdaq | 1 asset: 1 Ph 1 | PMN310Phase 1 · Alzheimer's Disease | Dec 2026PMN310 · Phase 1 | $28M | $44MSep 2026 | ~4.3 qtrs | $33M |
Aurinia PharmaceuticalsAUPH · Nasdaq | 2 assets: 1 approved, 1 Ph 2 | aritinerceptPhase 1/2 · Generalized Myasthenia Gravis | 2 Mar 2029aritinercept · Phase 1/2 | — | $487MSep 2026 | Cash-flow positive | $48M |
HLS Therapeutics Inc.HLS · TSX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
Knight TherapeuticsGUD · TSX | 6 assets: 6 approved | Approved assets only | Dec 2026viloxazine · Phase 3 | — | — | — | — |
35PharmaPrivate | 1 asset: 1 Ph 2 | HS235Phase 1/2 · Heart FailureWeak signal | Mar 2028HS235 · Phase 1/2 | — | — | — | — |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
ConjuChemPrivate | 1 asset: 1 Ph 3 | AlbenatidePhase 3 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
Thryv TherapeuticsPrivate | 1 asset: 1 Ph 1 | THRV-1268Phase 1 · Heart FailureWeak signal | 30 Jun 2027THRV-1268 · Phase 2/3 | — | — | — | — |
Verity PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.